Vedolizumab provides a new hope of acute graft-versus-host disease prophylaxis through immune regulation
-
-
REFERENCES
[1] Chen, Y.B., Kim, H.T., McDonough, S., et al. (2009). Up-Regulation of alpha4beta7 integrin on peripheral T cell subsets correlates with the development of acute intestinal graft-versus-host disease following allogeneic stem cell transplantation. Biol. Blood Marrow Transplant. 15: 1066−1076. DOI: 10.1016/j.bbmt.2009.05.003. [2] Chen, Y.B., Mohty, M., Zeiser, R., et al. (2024). Vedolizumab for the prevention of intestinal acute GVHD after allogeneic hematopoietic stem cell transplantation: A randomized phase 3 trial. Nat. Med. DOI: 10.1038/s41591-024-03016-4. [3] Watkins, B. and Williams, K.M. (2022). Controversies and expectations for the prevention of GVHD: A biological and clinical perspective. Front. Immunol. 13: 1057694. DOI: 10.3389/fimmu.2022.1057694. [4] Xu, L.P., Lu, D.P., Wu, D.P., et al. (2023). Hematopoietic stem cell transplantation activity in China 2020-2021 during the SARS-CoV-2 pandemic: A report from the Chinese Blood and Marrow Transplantation Registry Group. Transplant. Cell. Ther. 29: 136.e1−136.e7. DOI: 10.1016/j.jtct.2022.11.011. [5] Shen, M.Z., Hong, S.D., Lou, R., et al. (2022). A comprehensive model to predict severe acute graft-versus-host disease in acute leukemia patients after haploidentical hematopoietic stem cell transplantation. Exp. Hematol. Oncol. 11: 25. DOI: 10.1186/s40164-022-00278-x. -
ABOUT THIS ARTICLE
Cite this article:
Liu X., Cao L., Wu X., et al., (2024). Vedolizumab provides a new hope of acute graft-versus-host disease prophylaxis through immune regulation. The Innovation Medicine 2(3): 100083. https://doi.org/10.59717/j.xinn-med.2024.100083
Welcome!
To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.
Export File
Citation
Liu X., Cao L., Wu X., et al., (2024). Vedolizumab provides a new hope of acute graft-versus-host disease prophylaxis through immune regulation. The Innovation Medicine 2(3): 100083. https://doi.org/10.59717/j.xinn-med.2024.100083
Format
Content
DownLoad:
-
Figure 1.
(A) Annual number of HSCT recipients in the US and China reported by CIBMTR and CBMTR. (B) GradeⅡ-Ⅳ aGVHD incidence and mortality rate of severe lower-GI aGVHD. (C) Eligibility and randomization of the trial.2 (D) Frequence of lower-GI aGVHD by day +180 after allo-HSCT and primary study end point:lower-GI aGVHD free survival.2
